Key facts
- This page summarizes Andrew Sinclair's Form 4 filing for SOLENO THERAPEUTICS INC (SLNO).
- 0 reported transactions and 6 derivative rows are listed below.
- Accepted by SEC: 14 Oct 2022, 19:25.
Andrew Sinclair - 26 Aug 2022 Form 4 Insider Report for SOLENO THERAPEUTICS INC (SLNO)
- Reporting relationship
- Director
- Issuer ticker
- SLNO
- Reported as of
- 26 Aug 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Oct 2022, 19:25:50 UTC
- Prior SEC filing
- 01 Jul 2022
- Next SEC filing
- 26 May 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Anish Bhatnagar, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Andrew Sinclair filed Form 4 for SOLENO THERAPEUTICS INC (SLNO) on 14 Oct 2022.
Change
- Previous filing in this sequence was filed on 01 Jul 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SLNO
holding
Derivative
Stock option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,333
- Date
- 26 Aug 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,333
- Exercise price
- $23.55
- Footnotes
- F1, F2
SLNO
holding
Derivative
Stock option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 823
- Date
- 26 Aug 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 823
- Exercise price
- $39.45
- Footnotes
- F1, F3
SLNO
holding
Derivative
Stock option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 635
- Date
- 26 Aug 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 635
- Exercise price
- $51.15
- Footnotes
- F1, F3
SLNO
holding
Derivative
Stock option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,666
- Date
- 26 Aug 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,666
- Exercise price
- $33.60
- Footnotes
- F1, F3
SLNO
holding
Derivative
Stock option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,124
- Date
- 26 Aug 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,124
- Exercise price
- $15.30
- Footnotes
- F1, F3
SLNO
holding
Derivative
Stock option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,666
- Date
- 26 Aug 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,666
- Exercise price
- $2.55
- Footnotes
- F1, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The per share exercise price and number of shares subject to the option reflect the 1-for-15 reverse stock split effected August 26, 2022.
Footnote F2
One forty-eighth (1/48th) of the shares subject to the Option shall vest on the first month anniversary of December 21, 2018 (the "Vesting Commencement Date"), and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), such that all of the shares subject to the Option will have vested as of the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person continuing to be a Service Provider through each such date.
Footnote F3
All of the shares subject to this option are fully vested and exercisable as of the date hereof.
Footnote F4
The shares subject to the Option shall vest on the earlier of the twelve-month anniversary of June 1, 2022 or the day before the next annual stockholder meeting, subject to Reporting Person continuing to be a Service Provider through each such date.
SEC remarks
The Reporting Person is no longer deemed to share an indirect pecuniary interest in the securities held by Abingworth Bioventures VII, LP and therefore no longer reports those securities on his Section 16 reports.